Ipsen and Kartos Therapeutics Sign $1.75B Acquisition Deal
PARIS, France & REDWOOD CITY, Calif., June 29, 2026 Ipsen has announced a definitive agreement to acquire Kartos Therapeutics,...
phase III trial
Advertisement
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
Delphi Diagnostics Validates EAI for Paclitaxel Benefit
HOUSTON, Texas, June 22, 2026 Delphi Diagnostics has announced the publication of new clinical findings validating the predictive power...
Hamlet BioPharma Advances Alpha1H into Phase 3 Trial
LUND, Sweden, June 17, 2026 Hamlet BioPharma AB has reached a major clinical development milestone with the successful completion...
Merz Therapeutics and Teijin Secure Japan Approval for XEOMIN®
TOKYO, Japan and FRANKFURT, Germany, June 19, 2026 Teijin Pharma Limited and Merz Therapeutics GmbH have announced that Japan’s...
Advertisements
Boehringer Ingelheim Reports Survival Gains With Nerandomilast
INGELHEIM, Germany, June 18, 2026 Boehringer Ingelheim has announced new long-term survival modeling analyses from its pivotal Phase III...
HUTCHMED Reports Positive Phase III Sovleplenib Results in wAIHA
Hong Kong, Shanghai & Florham Park, N.J., June 12, 2026 HUTCHMED (China) Limited announced positive results from the Phase...
Akeso Wins NMPA Approval for Gumokimab in Plaque Psoriasis
HONG KONG, June 11, 2026 Akeso, Inc. announced that China’s National Medical Products Administration (NMPA) has approved gumokimab (AK111,...
Boehringer’s Survodutide Delivers Major Metabolic Benefits
INGELHEIM, Germany – June 7, 2026 Boehringer Ingelheim has reported positive Phase III results for its investigational glucagon/GLP-1 dual...
AstraZeneca’s Ultomiris Shows Strong IgAN Phase III Results
GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...
Advertisement
